Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.

Summary of Consolidated Financial Results(For the First Quarter ended June 30, 2024) [Under Japanese GAAP]
July 31, 2024
Tokyo Stock Exchange
Company name: KYORIN Pharmaceutical Co., Ltd.
Code number: 4569
Web site: https://www.kyorin-pharm.co.jp/
Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer
Contact: Sakurou Banba, Director, Finance & Accounting
TEL (03) 6374-9704
Scheduled date to commence dividend payments: —Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: None
(Amounts rounded down to the nearest million yen)
1. Consolidated results for the three months ended June 30, 2023 (from April 1, 2024 to June 30, 2024)(1) Consolidated operating results(Percentage changes relative to previous corresponding period)
Profit attributable toNet sales
Operating profit
Ordinary profit
owners of parent
Three months ended Million yen% Million yen% Million yen% Million yen%
June 30, 2024
28,419
2.0
1,150
32.0
1,417
32.0
885
12.4
June 30, 2023
27,854
13.1
871
1,074
787
－－－(Note) Comprehensive income: For the three months ended June 30, 2024: 1,173 million yen (－7.2%),
For the three months ended June 30, 2023: 1,264 million yen ( — %)Earnings per share (Basic)
Three months ended
June 30, 2024
June 30, 2023

Earnings per share (Diluted)

Yen
15.42
13.75

Yen
——(Note) Beginning this fiscal year, the company changed accounting policies. The results of the first quarter of fiscal year ended
March 31, 2024 and change are presented after retroactive adjustment.

(2) Consolidated financial position
Total assets
As ofJune 30, 2024
March 31, 2024

Net assets

Million yen
179,911
177,627

Equity ratio

Million yen
130,047
130,735

%
72.3
73.6

(Note) Equity: For the three months ended June 30, 2024: 130,047 million yen,
For the fiscal year ended March 31, 2024: 130,735 million yen(Note) Beginning this fiscal year, the company changed accounting policies. The results for fiscal year ended March 31, 2024 andchange are presented after retroactive adjustment.

2. Dividends
Annual dividends per share(Record date)Fiscal year ended
March 31, 2024
Fiscal year ended
March 31, 2025
Fiscal year ending
March 31, 2025
(Forecast)First quarter-end

Second quarter-end

Third quarter-end

Fiscal year-end

Total

Yen

Yen

Yen

Yen

Yen

—

20.00

—

32.00

52.00

20.00

—

32.00

52.00

—

(Note) Revisions to the dividend forecast in the current quarter: None1

3. Forecast of consolidated for the year ending March 31, 2025 (from April 1, 2024 to March 31, 2025)(Percentage changes relative to previous corresponding period)
Profit attributable to Earnings
Net sales
Operating profit
Ordinary profit
owners of parent
per share
Million yen% Million yen% Million yen% Million yen%Yen
First half
56,9003.6
1,000 －25.1
1,300 －17.7
900 －52.4
15.67
Full year
123,400
3.2
6,500
4.3
6,900
1.1
5,000
87.03
－8.7
(Note) Revisions to the dividend forecast in the current quarter: None
(Note) Percentage changes relative to previous corresponding period are presented after retroactive adjustment4. Other(1) Changes in significant subsidiaries during the period (Change in specified subsidiaries resulting in the scope ofconsolidation): None
Newly included: None, Excluded: None
(2) Adoption of accounting treatment specific to the preparation of quarterly financial statements : Yes(3) Changes in accounting policies, changes in accounting estimates and restatements(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None(ii) Changes in accounting policies due to other than (i): Yes(iii) Changes in accounting estimates: None(iv) Restatements: None(4) Number of shares issued (common stock)(i) Number of issued shares at the end of the period (including treasury shares)
As of June 30, 2024: 64,607,936 shares,
Fiscal year ended March 31 2024: 64,607,936 shares(ii) Number of treasury shares at the end of the period
As of June 30, 2024: 7,159, 315 shares,
Fiscal year ended March 31 2024: 7,159,151 shares(iii) Averaged number of shares of during the period
As of June 30, 2024: 57,448,675 shares,
As of June 30, 2023: 57,303,858 shares* This quarterly financial report is not subject to audit procedures by Certified Public Accountants or audit firm.
* Explanations about the appropriate use of the business forecasts and other noteworthy points.
These forecast performance figures are based on information currently available to the Company and may include
uncertain factors or risk that affect our future performance. Accordingly, actual business results may materiallydiffer from the forecasted figures due to various factors in the future.
(Methods for obtaining supplementary materials and content of financial results disclosure)
Supplementary materials will be made available on the Company’s website in conjunction with the Summary ofConsolidated Financial Results.

2